Top-News
  • Startseite
  • Aktien
  • Savara Aktie
  • News
  • Jetzt für 0€ handeln

    • Savara News

    1,58 $ +0,64% +0,01 $
    In : 1,4937 € | 27.06.22 22:00:01 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2DQ2B
    ISIN: US8051111016
    US-Symbol: SVRA
    Typ: Aktie

    Savara News

      
    < Zurück < Zurück
    von 8
    Weiter > Weiter >
    < Zurück < Zurück
    von 8
    Weiter > Weiter >
    16.06.22 - Businesswire
    Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an ...
    01.06.22 - Businesswire
    Savara to Present at Jefferies Healthcare Conference
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...
    17.05.22 - Businesswire
    Savara to Present at H.C. Wainwright Global Investment Conference
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...
    11.05.22 - Businesswire
    Savara Reports First Quarter 2022 Financial Results and Provides Business Update
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, ...
    26.04.22 - Businesswire
    Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new ...
    22.04.22 - Businesswire
    Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank
    Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it entered into a term loan agreement of ...
    30.03.22 - Businesswire
    Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update
    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a business ...
    17.03.21 - PR Newswire
    Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara?
    Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara? PR Newswire
    16.03.21 - PR Newswire
    Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health?
    Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health? PR Newswire
    02.04.19 - ACCESSWIRE
    Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London
    AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will ...
    13.03.19 - ACCESSWIRE
    Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update
    On-Track to Report Top Line Results from Pivotal Phase 3 IMPALA Study at End of Q2 2019
    06.03.19 - ACCESSWIRE
    Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019
    AUSTIN, TX / ACCESSWIRE / March 6, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its fourth quarter and year-end 2018 ...
    04.03.19 - ACCESSWIRE
    Savara to Present at the 39th Annual Cowen and Company Healthcare Conference
    AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob ...
    11.07.17 - PR Newswire
    Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension
    Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension Aironite Significantly ...
    20.06.17 - PR Newswire
    Savara Set To Join Russell Microcap® Index
    Savara Set To Join Russell Microcap® Index PR Newswire
    07.06.17 - PR Newswire
    Savara Announces Closing Of Public Offering Of Common Stock
    Savara Announces Closing Of Public Offering Of Common Stock PR Newswire
    05.06.17 - PR Newswire
    Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th
    Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th PR Newswire
    02.06.17 - PR Newswire
    Savara Announces Pricing Of Public Offering Of Common Stock
    Savara Announces Pricing Of Public Offering Of Common Stock PR Newswire
    01.06.17 - PR Newswire
    Savara Announces Proposed Public Offering Of Common Stock
    Savara Announces Proposed Public Offering Of Common Stock PR Newswire
    10.05.17 - PR Newswire
    Savara Announces Expedited U.S. Molgradex Development Strategy
    Savara Announces Expedited U.S. Molgradex Development Strategy Ongoing IMPALA Study to be Expanded to Serve as Global Pivotal Study for Registration PR Newswire
    < Zurück < Zurück
    von 8
    Weiter > Weiter >

    Newssuche

      

    Videos

      
    27.06.22
    Technical Trading - Kakao zum Monatsende Long
    Kakao Long OE Turbo Bull Hebel: 7 WKN: VQ9A2K Kauforder: Market Gültigkeit: tagesgültig Stop-Loss: 0,5 € ... Mehr »